Abstract
The aim of the study was to determine the prognostic value of expression levels of biomarkers selected on the basis of the literature: p53, Ki-67, survivin, β-catenin, E-cadherin and N-cadherin in patients with non-muscle invasive bladder cancer. Immunohistochemistry was performed on sections of primary papillary carcinoma of the bladder removed during transurethral resection of the tumor in 134 patients. The expression of β-catenin and E-cadherin was found in all analyzed cases and N-cadherin expression was demonstrated in 3.73% of the tissues examined. The expression of the p53 protein was confirmed in 96.27% of tissues examined. The expression of the Ki-67 protein was demonstrated in all analyzed cases. Survivin expression was found in 95.52% of the study group. Multivariate analysis confirmed the relationship between the recurrence-free survival (RFS) and the intensity of the nuclear reaction for p53 (HR 1417, 95% CI 1.001–2.007, p = 0.049) and survivin (HR 1.451; 95% CI 1.078–1.955; p = 0.014), the expression level of the Ki-67 protein expressed by the TS index (HR 1.146, 95% CI 1.116–1.823, p = 0.005) and the use of adjuvant BCG therapy (HR 0.218, 95% CI 0.097–0.489, p = 0.0002). The evaluation of Ki-67 expression and the intensity of nuclear staining for survivin and p53 may provide additional information that will allow more accurate stratification of the risk of NMIBC recurrence after TURBT.
Highlights
The basic treatment for bladder cancer diagnosed at the stage of non-muscle invasive bladder cancer (NMIBC) is transurethral resection of the bladder tumor (TURBT)
The material used for the study were clinical data from patients’ medical history and sections of low- and high-grade papillary urothelial carcinoma from the Department of General, Functional and Oncological Urology of the Military Institute of Medicine in Warsaw removed during transurethral resection of the bladder tumor between 2010 and 2015
The study group consisted of 134 patients (113 men and 21 women) with papillary non-muscle invasive bladder cancer
Summary
The basic treatment for bladder cancer diagnosed at the stage of non-muscle invasive bladder cancer (NMIBC) is transurethral resection of the bladder tumor (TURBT). The p53 protein is an important element regulating the cell cycle. A member of the inhibitor of apoptosis family, plays a role in the chromosomal segregation by regulating the transition from the G2 to M phase of the cell cycle. The Ki-67 protein, regarded as a proliferation marker, can be detected in the cell nuclei in the G1, S and G2 phases of the cell cycle and in mitosis. The function of this protein in the regulation of the cell cycle has not been clearly determined, but it has been shown that its presence is essential for the proliferation process [12]. Studies on transgenic mice have shown that increased activation of β-catenin causes hyperplasia of the bladder epithelium, which may precede the development of cancer [16]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
